1. Dimethyl fumarate protects against intestinal ischemia/reperfusion lesion: Participation of Nrf2/HO-1, GSK-3β and Wnt/β-catenin pathway.
- Author
-
Gendy A, Soubh A, Al-Mokaddem A, and Kotb El-Sayed M
- Subjects
- Animals, Antioxidants pharmacology, Apoptosis drug effects, Disease Models, Animal, Glycogen Synthase Kinase 3 beta genetics, Heme Oxygenase (Decyclizing) genetics, Intestinal Diseases enzymology, Intestinal Diseases genetics, Intestinal Diseases pathology, Intestines enzymology, Intestines pathology, Male, NF-E2-Related Factor 2 genetics, Nitrosative Stress drug effects, Rats, Wistar, Reperfusion Injury enzymology, Reperfusion Injury genetics, Reperfusion Injury pathology, Rats, Anti-Inflammatory Agents pharmacology, Dimethyl Fumarate pharmacology, Glycogen Synthase Kinase 3 beta metabolism, Heme Oxygenase (Decyclizing) metabolism, Intestinal Diseases prevention & control, Intestines drug effects, NF-E2-Related Factor 2 metabolism, Reperfusion Injury prevention & control, Wnt Signaling Pathway drug effects
- Abstract
Objective: Dimethyl fumarate (DMFU), a known Nrf2 activator, has proven its positive effect in different organs against ischemia/reperfusion (Is/Re) injury. Nevertheless, its possible impact to modulate intestinal Is/Re-induced injury has not been previously demonstrated before. Hence, this study aimed to investigate DMFU mechanistic maneuver against intestinal Is/Re., Methods: To accomplish this goal, Wistar rats were allocated into four groups; Sham-operated (SOP), intestinal Is/Re (1 h/6 h), and 14 days pre-treated DMFU (15 and 25 mg/kg/day, p.o)., Results: The mechanistic maneuver divulged that DMFU safeguarded the intestine partly via amplifying the expression/content of Nrf2 along with enhancing its downstream, HO-1 expression/content. In addition, DMFU lessened GSK-3β expression/content accompanied by enriching β-catenin expression/content. The antioxidant action was affirmed by enhancing total antioxidant capacity, besides reducing MDA, iNOS, and its by-product, NOx. The DMFU action entailed anti-inflammatory character manifested by down-regulation of expression/content NF-κB with subsequent rebating the contents of TNF-α, IL-1β, and P-selectin, as well as MPO activity. Moreover, DMFU had anti-apoptotic nature demonstrated through enriching Bcl-2 level and diminishing that of caspase-3., Conclusion: DMFU purveyed tenable novel protective mechanisms and mitigated events associated with intestinal Is/Re mischief either in the lower or the high dose partly by amending of oxidative stress and inflammation through the modulation of Nrf2/HO-1, GSK-3β, and Wnt/β-catenin pathways., (Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF